Universal Biosensors surges 60% on FDA approval for Class II device
Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical Laboratory Improvement Amendments Waiver approvals.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.